Corient Private Wealth
INBX icon

Corient Private Wealth’s Inhibrx INBX Stock Holding History

Corient Private Wealth’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.94M Sell
28,814
-12,072
-30% -$895K ﹤0.01% 1286
2025
Q4 		$3.23M Buy
+40,886
New +$2.79M ﹤0.01% 1265
2025
Q3 		– Sell
-20,455
Closed -$292K – 2623
2025
Q2 		$292K Hold
20,455
– – ﹤0.01% 2006
2025
Q1 		$286K Sell
20,455
-37
-0.2% -$502 ﹤0.01% 1880
2024
Q4 		$316K Buy
20,492
+6,667
+48% +$102K ﹤0.01% 1864
2024
Q3 		$217K Buy
+13,825
New +$194K ﹤0.01% 2194

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Corient Private Wealth's INBX Position: Q1 2026 in Review

Corient Private Wealth reduced its Inhibrx (INBX) stake by 30% in Q1 2026, selling an estimated $895K and leaving 28,814 shares worth $1.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1286.

Corient Private Wealth first reported a position in INBX in Q3 2024 and has held it in 6 quarters since. The position peaked at $3.23M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Corient Private Wealth held 28,814 shares of Inhibrx worth $1.94M as of Q1 2026.
  • Corient Private Wealth sold 12,072 Inhibrx shares in Q1 2026, an estimated $895K.
  • Inhibrx made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #1286 holding.
  • Corient Private Wealth first reported a position in Inhibrx in Q3 2024 and has held it in 6 quarters since.
  • Corient Private Wealth's Inhibrx position peaked at $3.23M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.